Trial Outcomes & Findings for The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems (NCT NCT02510820)

NCT ID: NCT02510820

Last Updated: 2017-02-01

Results Overview

Conjunctival hyperaemia of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

51 participants

Primary outcome timeframe

Baseline, 1 week, 2 weeks, 4 weeks

Results posted on

2017-02-01

Participant Flow

Three subjects were not dispensed the combination of multipurpose solutions.

Participant milestones

Participant milestones
Measure
Synergi/Comfilcon A Combo, Then Biotrue/Comfilcon A Combo
Participants were randomized to wear Synergi/comfilcon A combination for one month, then cross over to the alternative Biotrue/comfilcon A combination.
Biotrue/Comfilcon A Combo, Then Synergi/Comfilcon A Combo
Participants were randomized to wear Biotrue/comfilcon A combination for one month, then cross over to the alternative Synergi/comfilcon A combination.
First Intervention (4 Weeks)
STARTED
21
27
First Intervention (4 Weeks)
COMPLETED
21
26
First Intervention (4 Weeks)
NOT COMPLETED
0
1
Washout (1 Week)
STARTED
21
26
Washout (1 Week)
COMPLETED
21
26
Washout (1 Week)
NOT COMPLETED
0
0
Second Intervention (4 Weeks)
STARTED
21
26
Second Intervention (4 Weeks)
COMPLETED
20
26
Second Intervention (4 Weeks)
NOT COMPLETED
1
0

Reasons for withdrawal

Reasons for withdrawal
Measure
Synergi/Comfilcon A Combo, Then Biotrue/Comfilcon A Combo
Participants were randomized to wear Synergi/comfilcon A combination for one month, then cross over to the alternative Biotrue/comfilcon A combination.
Biotrue/Comfilcon A Combo, Then Synergi/Comfilcon A Combo
Participants were randomized to wear Biotrue/comfilcon A combination for one month, then cross over to the alternative Synergi/comfilcon A combination.
First Intervention (4 Weeks)
Withdrawal by Subject
0
1
Second Intervention (4 Weeks)
Withdrawal by Subject
1
0

Baseline Characteristics

The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall Baseline Characteristics
n=51 Participants
Participants were randomized to wear either the Synergi/comfilcon A or Biotrue/comfilcon A combination for one month, then cross over to the alternative combination.
Age, Continuous
33.3 years
STANDARD_DEVIATION 10.9 • n=5 Participants
Sex: Female, Male
Female
34 Participants
n=5 Participants
Sex: Female, Male
Male
17 Participants
n=5 Participants
Region of Enrollment
United Kingdom
51 participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline, 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Conjunctival hyperaemia of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Conjunctival Hyperaemia
Baseline
0.84 units on a scale
Standard Deviation 0.24
0.87 units on a scale
Standard Deviation 0.21
Conjunctival Hyperaemia
1 week
0.87 units on a scale
Standard Deviation 0.21
0.87 units on a scale
Standard Deviation 0.22
Conjunctival Hyperaemia
2 weeks
0.88 units on a scale
Standard Deviation 0.24
0.83 units on a scale
Standard Deviation 0.21
Conjunctival Hyperaemia
4 weeks
0.90 units on a scale
Standard Deviation 0.21
0.82 units on a scale
Standard Deviation 0.17

PRIMARY outcome

Timeframe: Baseline, 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Limbal hyperaemia of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Limbal Hyperaemia
Baseline
0.73 units on a scale
Standard Deviation 0.26
0.77 units on a scale
Standard Deviation 0.22
Limbal Hyperaemia
1 week
0.80 units on a scale
Standard Deviation 0.23
0.75 units on a scale
Standard Deviation 0.24
Limbal Hyperaemia
2 weeks
0.73 units on a scale
Standard Deviation 0.25
0.70 units on a scale
Standard Deviation 0.26
Limbal Hyperaemia
4 weeks
0.78 units on a scale
Standard Deviation 0.22
0.72 units on a scale
Standard Deviation 0.21

PRIMARY outcome

Timeframe: Baseline, 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Corneal staining of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=none, 4=patch.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Corneal Staining
Baseline
0.30 units on a scale
Standard Deviation 0.48
0.17 units on a scale
Standard Deviation 0.34
Corneal Staining
1 week
0.34 units on a scale
Standard Deviation 0.40
0.67 units on a scale
Standard Deviation 0.47
Corneal Staining
2 weeks
0.38 units on a scale
Standard Deviation 0.46
0.59 units on a scale
Standard Deviation 0.54
Corneal Staining
4 weeks
0.31 units on a scale
Standard Deviation 0.42
0.62 units on a scale
Standard Deviation 0.51

PRIMARY outcome

Timeframe: Baseline, 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Papillary conjunctivitis of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at baseline, 1 week, 2 week, and 4 week follow-up visits. Grades 0-4, 0=normal, 4=severe.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Papillary Conjunctivitis
1 week
1.05 units on a scale
Standard Deviation 0.24
1.04 units on a scale
Standard Deviation 0.23
Papillary Conjunctivitis
2 weeks
1.05 units on a scale
Standard Deviation 0.26
1.06 units on a scale
Standard Deviation 0.20
Papillary Conjunctivitis
Baseline
1.04 units on a scale
Standard Deviation 0.22
1.07 units on a scale
Standard Deviation 0.24
Papillary Conjunctivitis
4 weeks
1.09 units on a scale
Standard Deviation 0.24
1.06 units on a scale
Standard Deviation 0.24

PRIMARY outcome

Timeframe: 1 week

Subjective comfort for Synergi / comfilcon A combination and Biotrue / comfilcon A combination is assessed at 1 week visit. Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Comfort
Comfort after insertion
88.7 units on a scale
Standard Deviation 11.4
83.4 units on a scale
Standard Deviation 17.9
Comfort
Comfort before removal
76.8 units on a scale
Standard Deviation 17.2
72.4 units on a scale
Standard Deviation 22.4
Comfort
Overall comfort
85.6 units on a scale
Standard Deviation 11.8
82.8 units on a scale
Standard Deviation 13.9

PRIMARY outcome

Timeframe: 2 weeks

Population: The difference in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective comfort for Synergi / comfilcon A combination and Biotrue / comfilcon A combination is assessed at 2 week visit. Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=45 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Comfort
Comfort after insertion
87.0 units on a scale
Standard Deviation 12.6
85.6 units on a scale
Standard Deviation 14.8
Comfort
Comfort before removal
78.1 units on a scale
Standard Deviation 19.4
73.9 units on a scale
Standard Deviation 20.9
Comfort
Overall comfort
84.7 units on a scale
Standard Deviation 14.9
83.2 units on a scale
Standard Deviation 14.8

PRIMARY outcome

Timeframe: 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective comfort for Synergi / comfilcon A combination and Biotrue / comfilcon A combination is assessed at 4 week visit. Scale 0-100, 0=causes pain, cannot be tolerated, 100=excellent, cannot be felt.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=45 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=45 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Comfort
Comfort after insertion
88.3 units on a scale
Standard Deviation 11.0
87.3 units on a scale
Standard Deviation 15.5
Comfort
Comfort before removal
76.1 units on a scale
Standard Deviation 21.2
75.0 units on a scale
Standard Deviation 20.0
Comfort
Overall comfort
85.3 units on a scale
Standard Deviation 14.3
84.5 units on a scale
Standard Deviation 14.0

PRIMARY outcome

Timeframe: 1 week

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective assessment of vision for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 1 week visit. Scale 0-100, 0=extremely poor, intolerable levels of variation in vision, 100=excellent, no variation in vision.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Vision
Distance vision
91.1 units on a scale
Standard Deviation 12.7
92.1 units on a scale
Standard Deviation 10.4
Vision
Variable vision
92.1 units on a scale
Standard Deviation 12.7
92.1 units on a scale
Standard Deviation 12.4
Vision
Night vision
90.4 units on a scale
Standard Deviation 12.3
91.6 units on a scale
Standard Deviation 11.2

PRIMARY outcome

Timeframe: 2 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective assessment of vision for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 2 week visit. Scale 0-100, 0=extremely poor, intolerable levels of variation in vision, 100=excellent, no variation in vision.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=45 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Vision
Distance vision
92.8 units on a scale
Standard Deviation 8.7
91.1 units on a scale
Standard Deviation 13.0
Vision
Variable vision
94.3 units on a scale
Standard Deviation 9.6
90.5 units on a scale
Standard Deviation 12.3
Vision
Night vision
93.2 units on a scale
Standard Deviation 8.1
90.8 units on a scale
Standard Deviation 12.7

PRIMARY outcome

Timeframe: 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective assessment of vision for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 4 week visit. Scale 0-100, 0=extremely poor, intolerable levels of variation in vision, 100=excellent, no variation in vision.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=45 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=45 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Vision
Distance vision
92.5 units on a scale
Standard Deviation 8.8
92.6 units on a scale
Standard Deviation 10.4
Vision
Variable vision
92.6 units on a scale
Standard Deviation 12.5
94.1 units on a scale
Standard Deviation 9.5
Vision
Night vision
92.1 units on a scale
Standard Deviation 8.6
91.9 units on a scale
Standard Deviation 11.5

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Subjective assessment of dryness for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 1 week, 2 week, and 4 week visit. Scale 0-100, 0=extremely dry 100=not dry at all.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Dryness
4 weeks
79.9 units on a scale
Standard Deviation 20.9
81.7 units on a scale
Standard Deviation 20.3
Dryness
2 weeks
79.5 units on a scale
Standard Deviation 20.5
80.2 units on a scale
Standard Deviation 19.8
Dryness
1 week
82.8 units on a scale
Standard Deviation 16.3
79.3 units on a scale
Standard Deviation 20.0

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Subjective assessment of burning/stinging for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 1 week, 2 week, and 4 week visit. Scale 0-100, 0=Extreme stinging / burning, 100=No stinging / burning sensation.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Burning/Stinging
1 week
94.3 units on a scale
Standard Deviation 13.0
95.7 units on a scale
Standard Deviation 9.4
Burning/Stinging
2 weeks
96.0 units on a scale
Standard Deviation 8.4
96.8 units on a scale
Standard Deviation 8.7
Burning/Stinging
4 weeks
94.6 units on a scale
Standard Deviation 10.9
96.5 units on a scale
Standard Deviation 9.3

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective ocular redness of Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at 1 week, 2 week, and 4 week follow-up visits. Scale 0-100, 0=extremely poor. intolerable levels of redness, 100=excellent, no redness.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Ocular Redness
1 week
96.0 units on a scale
Standard Deviation 9.9
96.8 units on a scale
Standard Deviation 6.4
Ocular Redness
2 weeks
95.4 units on a scale
Standard Deviation 9.6
96.5 units on a scale
Standard Deviation 8.2
Ocular Redness
4 weeks
95.5 units on a scale
Standard Deviation 8.1
95.7 units on a scale
Standard Deviation 9.9

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective assessment of insertionfor Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 1 week, 2 week, and 4 week follow-up visits. Scale 0-100, 0=unmanageable. lenses impossible to insert, 100=excellent. no problem with lens insertion.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Ease of Lens Insertion
1 week
90.9 units on a scale
Standard Deviation 11.8
93.2 units on a scale
Standard Deviation 8.5
Ease of Lens Insertion
2 weeks
90.8 units on a scale
Standard Deviation 8.8
93.4 units on a scale
Standard Deviation 8.9
Ease of Lens Insertion
4 weeks
91.8 units on a scale
Standard Deviation 8.7
93.5 units on a scale
Standard Deviation 8.8

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Population: The differences in the sample size of the results vary due to lack of subjects attending their follow-up visits, however they completed the study.

Subjective assessment of removal for Synergi / comfilcon A combination and Biotrue / comfilcon A combination was assessed at 1 week, 2 week, and 4 week follow-up visits. Scale 0-100, 0=unmanageable. lenses impossible to remove, 100=excellent. no problem with lens remove.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Ease of Lens Removal
1 week
91.1 units on a scale
Standard Deviation 14.0
92.2 units on a scale
Standard Deviation 11.8
Ease of Lens Removal
2 weeks
90.7 units on a scale
Standard Deviation 11.9
94.0 units on a scale
Standard Deviation 10.5
Ease of Lens Removal
4 weeks
91.3 units on a scale
Standard Deviation 11.2
94.4 units on a scale
Standard Deviation 8.2

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Subjective ease of use for Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at 1 week, 2 week, and 4 week follow-up visit. Scale 0-100, 0=very difficult, 100=very easy

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=47 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=48 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Ease of Use of Solution
1 week
87.7 units on a scale
Standard Deviation 17.3
92.2 units on a scale
Standard Deviation 11.4
Ease of Use of Solution
2 weeks
88.2 units on a scale
Standard Deviation 17.5
93.6 units on a scale
Standard Deviation 11.0
Ease of Use of Solution
4 weeks
88.7 units on a scale
Standard Deviation 15.3
92.7 units on a scale
Standard Deviation 12.6

PRIMARY outcome

Timeframe: 1 week, 2 weeks, 4 weeks

Population: Data not collected as follows: 2 weeks (1 participant) and 4 weeks (1 participant - Synergi, 1 participant - Biotrue).

Subjective overall scores Synergi / comfilcon A combination and Biotrue / comfilcon A combination assessed at 1 week, 2 week, and 4 week follow-up visit. Scale 0-100, 0=extremely poor, 100=excellent, highly impressed.

Outcome measures

Outcome measures
Measure
Synergi / Comfilcon A
n=46 Participants
Participants were randomized to wear the Synergi / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Synergi: Multipurpose solution
Biotrue / Comfilcon A
n=47 Participants
Participants were randomized to wear the Biotrue / comfilcon A combination for one month during the cross over study. comfilcon A: soft contact lens Biotrue: Multipurpose solution
Overall Score
4 weeks
88.8 units on a scale
Standard Deviation 15.4
91.7 units on a scale
Standard Deviation 12.7
Overall Score
1 week
90.3 units on a scale
Standard Deviation 12.6
90.6 units on a scale
Standard Deviation 11.7
Overall Score
2 weeks
88.3 units on a scale
Standard Deviation 15.0
90.7 units on a scale
Standard Deviation 12.5

Adverse Events

Biotrue/Comfilcon A Combo, Then Synergi/Comfilcon A Combo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Synergi/Comfilcon A Combo, Then Biotrue/Comfilcon A Combo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sr. Manager Global Medical Scientific Affairs

CooperVision

Phone: (925) 621-3761

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER